Literature DB >> 20133626

A mutation of Ikbkg causes immune deficiency without impairing degradation of IkappaB alpha.

Owen M Siggs1, Michael Berger, Philippe Krebs, Carrie N Arnold, Celine Eidenschenk, Christoph Huber, Elaine Pirie, Nora G Smart, Kevin Khovananth, Yu Xia, Gerald McInerney, Gunilla B Karlsson Hedestam, David Nemazee, Bruce Beutler.   

Abstract

Null alleles of the gene encoding NEMO (NF-kappaB essential modulator) are lethal in hemizygous mice and men, whereas hypomorphic alleles typically cause a syndrome of immune deficiency and ectodermal dysplasia. Here we describe an allele of Ikbkg in mice that impaired Toll-like receptor signaling, lymph node formation, development of memory and regulatory T cells, and Ig production, but did not cause ectodermal dysplasia. Degradation of IkappaB alpha, which is considered a primary requirement for NEMO-mediated immune signaling, occurred normally in response to Toll-like receptor stimulation, yet ERK phosphorylation and NF-kappaB p65 nuclear translocation were severely impaired. This selective loss of function highlights the immunological importance of NEMO-regulated pathways beyond IkappaB alpha degradation, and offers a biochemical explanation for rare immune deficiencies in man.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20133626      PMCID: PMC2840324          DOI: 10.1073/pnas.0915098107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  35 in total

1.  Shared pathways of IkappaB kinase-induced SCF(betaTrCP)-mediated ubiquitination and degradation for the NF-kappaB precursor p105 and IkappaBalpha.

Authors:  V Heissmeyer; D Krappmann; E N Hatada; C Scheidereit
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

2.  Specific missense mutations in NEMO result in hyper-IgM syndrome with hypohydrotic ectodermal dysplasia.

Authors:  A Jain; C A Ma; S Liu; M Brown; J Cohen; W Strober
Journal:  Nat Immunol       Date:  2001-03       Impact factor: 25.606

3.  A novel X-linked disorder of immune deficiency and hypohidrotic ectodermal dysplasia is allelic to incontinentia pigmenti and due to mutations in IKK-gamma (NEMO).

Authors:  J Zonana; M E Elder; L C Schneider; S J Orlow; C Moss; M Golabi; S K Shapira; P A Farndon; D W Wara; S A Emmal; B M Ferguson
Journal:  Am J Hum Genet       Date:  2000-10-24       Impact factor: 11.025

4.  Female mice heterozygous for IKK gamma/NEMO deficiencies develop a dermatopathy similar to the human X-linked disorder incontinentia pigmenti.

Authors:  C Makris; V L Godfrey; G Krähn-Senftleben; T Takahashi; J L Roberts; T Schwarz; L Feng; R S Johnson; M Karin
Journal:  Mol Cell       Date:  2000-06       Impact factor: 17.970

5.  NEMO/IKK gamma-deficient mice model incontinentia pigmenti.

Authors:  M Schmidt-Supprian; W Bloch; G Courtois; K Addicks; A Israël; K Rajewsky; M Pasparakis
Journal:  Mol Cell       Date:  2000-06       Impact factor: 17.970

6.  Deficient natural killer cell cytotoxicity in patients with IKK-gamma/NEMO mutations.

Authors:  Jordan S Orange; Scott R Brodeur; Ashish Jain; Francisco A Bonilla; Lynda C Schneider; Roberto Kretschmer; Samuel Nurko; Wendy L Rasmussen; Julia R Köhler; Stephen E Gellis; Betsy M Ferguson; Jack L Strominger; Jonathan Zonana; Narayanaswamy Ramesh; Zuhair K Ballas; Raif S Geha
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

7.  Gene defect in ectodermal dysplasia implicates a death domain adapter in development.

Authors:  D J Headon; S A Emmal; B M Ferguson; A S Tucker; M J Justice; P T Sharpe; J Zonana; P A Overbeek
Journal:  Nature       Date:  2001 Dec 20-27       Impact factor: 49.962

8.  Genomic rearrangement in NEMO impairs NF-kappaB activation and is a cause of incontinentia pigmenti. The International Incontinentia Pigmenti (IP) Consortium.

Authors:  A Smahi; G Courtois; P Vabres; S Yamaoka; S Heuertz; A Munnich; A Israël; N S Heiss; S M Klauck; P Kioschis; S Wiemann; A Poustka; T Esposito; T Bardaro; F Gianfrancesco; A Ciccodicola; M D'Urso; H Woffendin; T Jakins; D Donnai; H Stewart; S J Kenwrick; S Aradhya; T Yamagata; M Levy; R A Lewis; D L Nelson
Journal:  Nature       Date:  2000-05-25       Impact factor: 49.962

9.  Requirement of NF-kappaB/Rel for the development of hair follicles and other epidermal appendices.

Authors:  R Schmidt-Ullrich; T Aebischer; J Hülsken; W Birchmeier; U Klemm; C Scheidereit
Journal:  Development       Date:  2001-10       Impact factor: 6.868

10.  IkappaB kinase signaling is essential for maintenance of mature B cells.

Authors:  Manolis Pasparakis; Marc Schmidt-Supprian; Klaus Rajewsky
Journal:  J Exp Med       Date:  2002-09-16       Impact factor: 14.307

View more
  16 in total

1.  iRhom2 is required for the secretion of mouse TNFα.

Authors:  Owen M Siggs; Nengming Xiao; Ying Wang; Hexin Shi; Wataru Tomisato; Xiaohong Li; Yu Xia; Bruce Beutler
Journal:  Blood       Date:  2012-05-01       Impact factor: 22.113

Review 2.  Systems-level analysis of innate immunity.

Authors:  Daniel E Zak; Vincent C Tam; Alan Aderem
Journal:  Annu Rev Immunol       Date:  2014       Impact factor: 28.527

3.  MyD88 signaling in nonhematopoietic cells protects mice against induced colitis by regulating specific EGF receptor ligands.

Authors:  Katharina Brandl; Lei Sun; Christina Neppl; Owen M Siggs; Sylvain M Le Gall; Wataru Tomisato; Xiaohong Li; Xin Du; Daniela N Maennel; Carl P Blobel; Bruce Beutler
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-01       Impact factor: 11.205

Review 4.  Resisting viral infection: the gene by gene approach.

Authors:  Eva Marie Y Moresco; Bruce Beutler
Journal:  Curr Opin Virol       Date:  2011-11-06       Impact factor: 7.090

5.  Systems analysis identifies an essential role for SHANK-associated RH domain-interacting protein (SHARPIN) in macrophage Toll-like receptor 2 (TLR2) responses.

Authors:  Daniel E Zak; Frank Schmitz; Elizabeth S Gold; Alan H Diercks; Jacques J Peschon; Joe S Valvo; Antti Niemistö; Irina Podolsky; Shannon G Fallen; Rosa Suen; Tetyana Stolyar; Carrie D Johnson; Kathleen A Kennedy; M Kristina Hamilton; Owen M Siggs; Bruce Beutler; Alan Aderem
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-27       Impact factor: 11.205

6.  Congenital alterations of NEMO glutamic acid 223 result in hypohidrotic ectodermal dysplasia and immunodeficiency with normal serum IgG levels.

Authors:  Gital Karamchandani-Patel; Eric P Hanson; Rushani Saltzman; C Eve Kimball; Ricardo U Sorensen; Jordan S Orange
Journal:  Ann Allergy Asthma Immunol       Date:  2011-05-04       Impact factor: 6.347

7.  Defective nuclear IKKα function in patients with ectodermal dysplasia with immune deficiency.

Authors:  Stephane T Temmerman; Chi A Ma; Yongge Zhao; Jeffrey Keenan; Ivona Aksentijevich; Margaret Fessler; Margaret R Brown; Alan Knutsen; Ralph Shapiro; Ashish Jain
Journal:  J Clin Invest       Date:  2011-12-12       Impact factor: 14.808

8.  Recruitment of A20 by the C-terminal domain of NEMO suppresses NF-κB activation and autoinflammatory disease.

Authors:  Jevgenia Zilberman-Rudenko; Linda Monaco Shawver; Alex W Wessel; Yongquan Luo; Martin Pelletier; Wanxia Li Tsai; Younglang Lee; Spiridon Vonortas; Laurence Cheng; Jonathan D Ashwell; Jordan S Orange; Richard M Siegel; Eric P Hanson
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-22       Impact factor: 11.205

9.  RNA and imidazoquinolines are sensed by distinct TLR7/8 ectodomain sites resulting in functionally disparate signaling events.

Authors:  Elif Colak; Alasdair Leslie; Kieran Zausmer; Elham Khatamzas; Andriy V Kubarenko; Tica Pichulik; Sascha N Klimosch; Alice Mayer; Owen Siggs; Andreas Hector; Roman Fischer; Benedikt Klesser; Anna Rautanen; Martin Frank; Adrian V S Hill; Bénédicte Manoury; Bruce Beutler; Dominik Hartl; Alison Simmons; Alexander N R Weber
Journal:  J Immunol       Date:  2014-05-09       Impact factor: 5.422

Review 10.  Molecular control of the NEMO family of ubiquitin-binding proteins.

Authors:  Kristopher Clark; Sambit Nanda; Philip Cohen
Journal:  Nat Rev Mol Cell Biol       Date:  2013-08-29       Impact factor: 94.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.